BCYC News and Press, Bicycle Therapeutics plc From 09/10/20

The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating Bicycle Therapeutics' (NASDAQ: BCYC ) BT8009, a Bicycle Toxin Conjugate (BTC) targeting a tumor antigen called nectin-4, in patients with advanced solid tumors. More news on: Bicycle Therapeutics plc,...

- BT8009 is the third program designed to explore the potential of Bicycles® as next-generation tumor-targeting agents - BT8009 targets Nectin-4, a well-validated tumor antigen shown to be overexpressed in several common tumor types Bicycle Therapeutics plc (NASDAQ: BCY...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in the following virtual investor conferences i...

- Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be selected using prespecified tumor membrane H-scores for MT1-MMP ex...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first patient has been dosed in Oxurion’s Phase II study of TH...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical O...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in a fireside chat at the Canaccord Genuity 40 ...

Bicycle Therapeutics (NASDAQ: BCYC ) : Q2 GAAP EPS of -$0.67 misses by $0.16 . More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- Progress across pipeline continues with BT1718 Phase IIa and BT8009 Phase I/II trial initiations on-track for this year - Cash was $96.9 million at June 30, 2020, which excludes $17.6 million net proceeds from ATM offering program and a $6.7 million UK R&D tax credit, both receiv...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scie...